TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18358589

Group type: EXPERIMENTAL
Intervention: Bone marrow-derived stem cells or circulating progenitor cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bone marrow-origin stem cells
Number of subjects: 0
Study: 16491109

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 15488350

Group type: EXPERIMENTAL
Intervention: Continuous estrogen and progesterone in combination (Group III)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Cyclic estrogen and progesterone combination (Group IV)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Estrogen only (Control Group I)
Number of subjects: 82
Study: 11787909

Group type: EXPERIMENTAL
Intervention: Veda-scope
Number of subjects: 124

Group type: COMPARATOR
Intervention: bivalve speculum
Number of subjects: 124
Study: 9437560

Group type: EXPERIMENTAL
Intervention: DMPA (Depo-Provera) administered every 3 months
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Microgynon administered monthly
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (surgically sterilized patients)
Number of subjects: 43
Study: 8321981

Group type: EXPERIMENTAL
Intervention: Carbon dioxide laser
Number of subjects: 6

Group type: COMPARATOR
Intervention: Electrosurgery
Number of subjects: 6

Group type: COMPARATOR
Intervention: Both groups (Carbon dioxide laser and Electrosurgery)
Number of subjects: 6
Study: 3112720

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (SCG)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 29934224

Group type: EXPERIMENTAL
Intervention: Simplified regimen (3×12 J/cm2, without cleaning)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Standard regimen (2×15 J/cm2, followed by cleaning, followed by 2×15 J/cm2)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Simplified regimen
Number of subjects: 84

Group type: COMPARATOR
Intervention: Standard regimen
Number of subjects: 84
Study: 29025229

Group type: EXPERIMENTAL
Intervention: SVF-enriched fat transfer
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (washed adipose tissue)
Number of subjects: 30
Study: 26119653

Group type: EXPERIMENTAL
Intervention: Optimal Medical Therapy (OMT) and revascularization
Number of subjects: 20663

Group type: COMPARATOR
Intervention: No OMT and nonrevascularized
Number of subjects: 20663

Group type: EXPERIMENTAL
Intervention: OMT and no revascularization
Number of subjects: 20663

Group type: EXPERIMENTAL
Intervention: No OMT and revascularization
Number of subjects: 20663
Study: 23773733

Group type: EXPERIMENTAL
Intervention: Fasudil (0.9 mg/dL)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Papaverine (0.4 mg/mL mixed with heparinized blood)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparison of GFF between groups
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Histopathologic examination after fasudil injection
Number of subjects: 30
Study: 21118745

Group type: EXPERIMENTAL
Intervention: Generic test formulation (3 tablets of 200 mg each)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Branded reference formulation (1 tablet of 600 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 24
Study: 19033843

Group type: EXPERIMENTAL
Intervention: Propofol plus opioid (fentanyl or alfentanil)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Propofol only (no opioid)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Propofol plus midazolam
Number of subjects: 81
Study: 16377918

Group type: EXPERIMENTAL
Intervention: Combined therapy with atorvastatin (20 mg/day) and colestimide (3 g/day)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Intensive monotherapy with atorvastatin (40 mg/day)
Number of subjects: 17
Study: 12535748

Group type: EXPERIMENTAL
Intervention: Aldosterone 2.5 pmol/min
Number of subjects: 10
Study: 10830460

Group type: EXPERIMENTAL
Intervention: Nebulized surfactant (Curosurf)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (no nebulized material, same CPAP support)
Number of subjects: 34
Study: 9027648

Group type: EXPERIMENTAL
Intervention: Hydrophilic heparinized catheters
Number of subjects: 46

Group type: COMPARATOR
Intervention: Silicone catheters
Number of subjects: 46
Study: 1875601

Group type: EXPERIMENTAL
Intervention: Nifedipine (routine drug dose tests at rest and during isometric and dynamic exercise)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol (dynamic exercise test)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (routine drug dose tests at rest and during isometric and dynamic exercise)
Number of subjects: 0
Study: 6594492

Group type: EXPERIMENTAL
Intervention: Imipenem 10 mg/kg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Imipenem 25 mg/kg
Number of subjects: 13
Study: 30628511

Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (ASCT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 30701858

Group type: EXPERIMENTAL
Intervention: Bone marrow mesenchymal stromal cells (MSC) therapy (local and systemic administration)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Anticytokine therapy with infliximab (IFX)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Antibiotic (AB) and immunosuppressive (IS) therapy
Number of subjects: 36
Study: 27965998

Group type: EXPERIMENTAL
Intervention: Colchicine 1.0 mg per day for six weeks
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo for six weeks
Number of subjects: 33
Study: 24360934

Group type: EXPERIMENTAL
Intervention: ipsilesional M1 intermittent TBS (iTBSiM1)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: contralesional M1 continuous TBS (cTBScM1)
Number of subjects: 13

Group type: COMPARATOR
Intervention: sham TBS
Number of subjects: 13
Study: 23003329

Group type: EXPERIMENTAL
Intervention: iBolus
Number of subjects: 12

Group type: COMPARATOR
Intervention: tBolus
Number of subjects: 12
Study: 20194916

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (alpha‐tocopherol 400 mg/day)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 18259085

Group type: EXPERIMENTAL
Intervention: Tryptophan depletion
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 16610166

Group type: COMPARATOR
Intervention: Diet alone (Group I)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Hydroxymethylglutaryl coenzyme A reductase inhibitors (simvastatin) 10 mg/day plus diet (Group II)
Number of subjects: 84
Study: 12095096

Group type: EXPERIMENTAL
Intervention: 1% fusidic acid viscous drops (Fucithalmic)
Number of subjects: 484

Group type: COMPARATOR
Intervention: 0.3% tobramycin drops (Tobrex)
Number of subjects: 484
Study: 10438046

Group type: EXPERIMENTAL
Intervention: HBV/MF59 vaccine (2 or 3 immunizations)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: HBV/MF59 vaccine (2 doses, 2 months apart)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: HBV/MF59 vaccine (3 injections)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Licensed control vaccine (Recombivax HB)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: HBV/MF59 vaccine
Number of subjects: 230
Study: 7495044

Group type: EXPERIMENTAL
Intervention: Cilazapril 2.5 mg/day
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Cilazapril 5 mg/day
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Cilazapril (both doses)
Number of subjects: 34
Study: 2191752

Group type: EXPERIMENTAL
Intervention: Vacuum drainage (n = 65)
Number of subjects: 127

Group type: COMPARATOR
Intervention: No drainage (n = 62)
Number of subjects: 127
Study: 380933

Group type: EXPERIMENTAL
Intervention: Neomycin ointment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 0
Study: 31502945

Group type: EXPERIMENTAL
Intervention: internet-delivered dialectical behavior therapy (iDBT)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 59
Study: 30642922

Group type: EXPERIMENTAL
Intervention: Iclaprim
Number of subjects: 790
Study: 29191235

Group type: EXPERIMENTAL
Intervention: Chiropractic doctors (DCs) seeing pediatric patients
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: Naturopathic doctors (NDs) seeing pediatric patients
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: Post-graduate training
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: Self-assessment of pediatric training
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: Experience and post-graduate training
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: Broad array of pediatric health concerns addressed by DCs and NDs
Number of subjects: 643
Study: 26919405

Group type: EXPERIMENTAL
Intervention: 96-hour ketamine infusion (0.6 mg/kg/h target rate) with clonidine (max 0.6 mg orally daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 40-minute ketamine infusion (0.5 mg/kg) with clonidine (max 0.6 mg orally daily)
Number of subjects: 20
Study: 25796855

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome group (85 children)
Number of subjects: 155
Study: 23232195

Group type: EXPERIMENTAL
Intervention: Oral prednisolone (50 mg daily for 2 weeks)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS) (200 micrograms twice daily for 10 weeks)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Oral prednisolone (50 mg) and MFNS
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Oral prednisolone (50 mg)
Number of subjects: 114
Study: 21491823

Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg orally once daily for 6 months (Group A)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg vaginally once daily for 6 months (Group B)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Hygienodietetics advice and psychological support for 6 months (Group C)
Number of subjects: 64
Study: 17363838

Group type: EXPERIMENTAL
Intervention: 3-weekly combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone or cyclophosphamide, mitoxantrone, vincristine and prednisone (CNOP) chemotherapy with or without filgrastim
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Prophylactic intrathecal methotrexate
Number of subjects: 444
Study: 15117300

Group type: COMPARATOR
Intervention: VCT at the local clinic
Number of subjects: 2445

Group type: EXPERIMENTAL
Intervention: VCT at an optional location
Number of subjects: 2445
Study: 11908491

Group type: EXPERIMENTAL
Intervention: Cyclical sodium fluoride (NaF) 60 mg/day (6 months on, 3 months off) + calcium (1.0-1.2 g daily) + ergocalciferol (0.25 mg per 25 kg once weekly)
Number of subjects: 99

Group type: COMPARATOR
Intervention: No sodium fluoride (NaF) + calcium (1.0-1.2 g daily) + ergocalciferol (0.25 mg per 25 kg once weekly)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Cyclical sodium fluoride (NaF) in F CaD group
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Cyclical sodium fluoride (NaF) in FE CaD group
Number of subjects: 99

Group type: COMPARATOR
Intervention: Cyclical sodium fluoride (NaF) in CaD group
Number of subjects: 99

Group type: COMPARATOR
Intervention: Cyclical sodium fluoride (NaF) in E CaD group
Number of subjects: 99
Study: 10102784

Group type: EXPERIMENTAL
Intervention: D-fenfluramine (DFEN) with dexamethasone (DEX) pretreatment
Number of subjects: 8

Group type: COMPARATOR
Intervention: D-fenfluramine (DFEN) without dexamethasone (DEX) pretreatment
Number of subjects: 8
Study: 7606960

Group type: EXPERIMENTAL
Intervention: Four different levels of pressure support
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Pmusc(t)
Number of subjects: 8
Study: 2240381

Group type: EXPERIMENTAL
Intervention: Immediate shoulder exercises starting 1 day postoperatively (n = 78)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Delayed shoulder exercises starting on the eighth postoperative day (n = 66)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 144
Study: 837325

Group type: EXPERIMENTAL
Intervention: Sputum cytology every four months in addition to annual PA and lateral chest x‐rays
Number of subjects: 6612

Group type: COMPARATOR
Intervention: Annual PA and lateral chest x‐rays alone
Number of subjects: 6612
Study: 30919782

Group type: EXPERIMENTAL
Intervention: Sertraline 100 mg/day
Number of subjects: 36

Group type: COMPARATOR
Intervention: Rifampin 300 mg/day
Number of subjects: 36
Study: 27896520

Group type: EXPERIMENTAL
Intervention: Bevacizumab with or without carboplatin
Number of subjects: 15
Study: 25367253

Group type: EXPERIMENTAL
Intervention: Physical therapy intervention including manual therapy and exercise or electrophysiological agents and exercise
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Physical therapy intervention
Number of subjects: 60
Study: 24470716

Group type: EXPERIMENTAL
Intervention: 20mg oral isotretinoin once daily for 16 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: 20mg oral isotretinoin once daily along with 20% SA peels every two weeks for 16 weeks
Number of subjects: 60
Study: 20647952

Group type: EXPERIMENTAL
Intervention: Natural Grass (NG)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Artificial Turf (AT)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Hard Surface (HS)
Number of subjects: 8
Study: 19433689

Group type: EXPERIMENTAL
Intervention: Immediate postoperative radiotherapy (RT)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Wait-and-see policy (Control)
Number of subjects: 307
Study: 16116336

Group type: EXPERIMENTAL
Intervention: Statins (simvastatin or pravastatin, 10‐20 mg/d; atorvastatin, 5‐10 mg/d)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control (soy lecithin, 20 g/d)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Statins (for normotensive patients)
Number of subjects: 74
Study: 10477838

Group type: EXPERIMENTAL
Intervention: Corticosteroid withdrawal from 10 to 5 mg of prednisone (n = 21)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Corticosteroid withdrawal from 5 to 0 mg of prednisone (n = 17)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 14-day prednisone taper in 5 patients
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Corticosteroid withdrawal overall (n = 21)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Corticosteroid withdrawal
Number of subjects: 26
Study: 7807035

Group type: EXPERIMENTAL
Intervention: Nebulized bacteriostatic saline (3 mL, four times a day for 2 weeks)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nebulized saline (placebo) (3 mL, four times a day for 2 weeks)
Number of subjects: 10
Study: 1774911

Group type: EXPERIMENTAL
Intervention: Enterosorbent (high‐porous, small‐spherical fraction of CKH carbon)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 7124593

Group type: EXPERIMENTAL
Intervention: Verapamil (0.075 and 0.15 mg/kg, not exceeding 10 mg per dose)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 31678149

Group type: EXPERIMENTAL
Intervention: EX‐60 (30 min of exercise 60 min before lunch)
Number of subjects: 15

Group type: COMPARATOR
Intervention: CON (rest without exercise)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: EX‐60
Number of subjects: 15

Group type: COMPARATOR
Intervention: CON
Number of subjects: 15
Study: 30785773

Group type: EXPERIMENTAL
Intervention: Low-calorie diet (LCD)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Low-calorie diet plus interval exercise training (LCD+INT)
Number of subjects: 24
Study: 30219986

Group type: EXPERIMENTAL
Intervention: Citalopram 30 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27777201

Group type: EXPERIMENTAL
Intervention: Intravenous injection of methylene blue and lidocaine plus oral valaciclovir (group A)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Intravenous injection of lidocaine plus oral valaciclovir (group B)
Number of subjects: 64
Study: 24161074

Group type: EXPERIMENTAL
Intervention: Aspirin alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: DASA with or without concurrent aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 0
Study: 22742720

Group type: EXPERIMENTAL
Intervention: Alphacalcidol 0.25 μg once daily for two weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sevelamer carbonate 800 mg TID with meals for two weeks
Number of subjects: 19
Study: 19548438

Group type: EXPERIMENTAL
Intervention: Shenkangbao (SKB) at a dose of 10 g twice a day for 3 weeks
Number of subjects: 72

Group type: COMPARATOR
Intervention: Nifedipine 10 mg three times per day
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Shenkangbao (SKB)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 72
Study: 17611937

Group type: EXPERIMENTAL
Intervention: Combined therapy (psychotherapy + pharmacotherapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pharmacotherapy
Number of subjects: 0
Study: 15109971

Group type: EXPERIMENTAL
Intervention: Operant-behavioral treatment plus cognitive coping skills training
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Group discussion
Number of subjects: 148

Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 148
Study: 12181375

Group type: EXPERIMENTAL
Intervention: Influenza immunization
Number of subjects: 0
Study: 9655713

Group type: EXPERIMENTAL
Intervention: L-NAME 170 mg
Number of subjects: 22

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: L-NAME
Number of subjects: 22
Study: 7640430

Group type: EXPERIMENTAL
Intervention: C2 samples taken after slowing down blood flow rate (Qb) to 100 ml per min for 3 min (C2-100)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: C2 samples taken after stopping the blood pump for 1 min (C2-100-stop)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: C2 samples taken with Qb restored to 100 ml per min and the venous line clamped for 12 sec (C2-100-clamp)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: C2 samples taken after slowing down blood flow rate (Qb) to 50 ml per min for 3 min (C2-50)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: C2 samples taken after stopping the blood pump for 1 min (C2-50-stop)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: C2 samples taken with Qb slowed down to 50 ml per min and the venous line clamped (C2-50-clamp)
Number of subjects: 22
Study: 31808359

Group type: EXPERIMENTAL
Intervention: Proximal medial gastrocnemius release (PMGR)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Open plantar fasciotomy (OPF)
Number of subjects: 36
Study: 29535132

Group type: EXPERIMENTAL
Intervention: MitraClip
Number of subjects: 87

Group type: COMPARATOR
Intervention: Mitral valve repair
Number of subjects: 87
Study: 28784673

Group type: EXPERIMENTAL
Intervention: Finafloxacin (single doses of 200 to 1,000 mg)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Finafloxacin (multiple doses of 600 to 1,000 mg)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 26269239

Group type: EXPERIMENTAL
Intervention: Pakistani almonds (10 g/d)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: American almonds (10 g/d)
Number of subjects: 150

Group type: COMPARATOR
Intervention: No intervention (NI)
Number of subjects: 150
Study: 24037607

Group type: EXPERIMENTAL
Intervention: Perceptual learning treatment for the amblyopic eye
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 20
Study: 21359508

Group type: EXPERIMENTAL
Intervention: Reboxetine (8 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Citalopram (40 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 19900256

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 668

Group type: COMPARATOR
Intervention: Interferon-alfa
Number of subjects: 668
Study: 17349073

Group type: EXPERIMENTAL
Intervention: SFA-rich diet (38% fat, 20% SFA)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: CHO-rich diet (30% fat, 55% CHO)
Number of subjects: 59

Group type: COMPARATOR
Intervention: MUFA-rich diet (38% fat, 22% MUFA)
Number of subjects: 59
Study: 15529479

Group type: EXPERIMENTAL
Intervention: Competitive work
Number of subjects: 103

Group type: COMPARATOR
Intervention: Community-based activities
Number of subjects: 103

Group type: COMPARATOR
Intervention: No regular daily activity
Number of subjects: 103
Study: 11573525

Group type: EXPERIMENTAL
Intervention: Propofol 2 microg ml(‐1)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Propofol 3 microg ml(‐1)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Propofol 4 microg ml(‐1)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Propofol 5 microg ml(‐1)
Number of subjects: 15
Study: 9590490

Group type: EXPERIMENTAL
Intervention: Early Recovery (ER) patients
Number of subjects: 23

Group type: COMPARATOR
Intervention: Late Recovery (LR) patients
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Overall recovery of WBC
Number of subjects: 23
Study: 7823493

Group type: EXPERIMENTAL
Intervention: Sound vibration therapy with 2.5 kHz and 0.66 W/cm2 intensity
Number of subjects: 31
Study: 2841742

Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg once a day
Number of subjects: 237

Group type: COMPARATOR
Intervention: Standard heparin 5000 IU t.d.s.
Number of subjects: 237
Study: 29386007

Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment (CGA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 28625372

Group type: EXPERIMENTAL
Intervention: Subcutaneous implantable cardioverter defibrillator
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 25965706

Group type: EXPERIMENTAL
Intervention: Edoxaban (60 mg QD or 30 mg QD depending on factors)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enoxaparin/warfarin followed by warfarin alone
Number of subjects: 0
Study: 23396280

Group type: EXPERIMENTAL
Intervention: Vorapaxar (2.5 mg daily)
Number of subjects: 4883

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4883
Study: 20925970

Group type: EXPERIMENTAL
Intervention: Real rTMS (high-frequency rTMS delivered to the left dorsolateral prefrontal cortex)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 22
Study: 18178525

Group type: EXPERIMENTAL
Intervention: IGIV-C (Gamunex)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117